Rising financial and regulatory pressures: Regulatory and financial pressures around adverse events and drug safety are intensifying. The costs associated with adverse effects morbidity and mortality are rising, accounting for billions of dollars and euros annually.

Multi-sourcing and cross-referencing: Most pharmas have access to adverse events data from regulatory sources, but few also take advantage of social media streams and clinical records. Only Data2Life combines data from regulatory bodies (the FDA and Health Canada), with social media and more than 4.5 million anonymized electronic health records.

Signal detection methodology: Data2Life doesn’t just capture and provide access to raw data, but makes it more accessible and usable for researchers, PV teams, risk and legal professionals and others. We normalize, transform, filter and classify data and then offer proprietary algorithms and advanced validation techniques that enable users to detect patterns and assess side effects signal, including therapeutic and positive side effects that may suggest new indications and repurposing opportunities for existing drugs.

Experience, leadership and expertise: Our leadership team and advisory group includes proven healthcare innovators and renowned researchers who have focused their careers on advancing the state of health intelligence and using data to improve risk management in healthcare.

Partnerships and alliances: Our direct engagement and ongoing collaboration with Clalit Health Services and other leading healthcare organizations help ensure that Data2Life’s products serve the needs of the healthcare industry and reflect the market’s leading edge.